AR064343A1 - Metodo para mejorar la apariencia corporal - Google Patents

Metodo para mejorar la apariencia corporal

Info

Publication number
AR064343A1
AR064343A1 ARP070105610A ARP070105610A AR064343A1 AR 064343 A1 AR064343 A1 AR 064343A1 AR P070105610 A ARP070105610 A AR P070105610A AR P070105610 A ARP070105610 A AR P070105610A AR 064343 A1 AR064343 A1 AR 064343A1
Authority
AR
Argentina
Prior art keywords
methyl
biphenyl
amide
quinolin
carbonyl
Prior art date
Application number
ARP070105610A
Other languages
English (en)
Inventor
Mary Anne Hickman
Jacques Gossellin
Jody Ann Wren
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR064343A1 publication Critical patent/AR064343A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

Un método para tratar a un sujeto que padece de obesidad o de trastornos alimenticios relacionados y/o para reducir el consumo de alimentos, y para mejorar la apariencia corporal comprendiendo el procedimiento administrar al sujeto una cantidad terapéuticamente eficaz de un inhibidor del MTP junto con una dieta incrementada en grasas. Reivindicacion 7: Un método o uso segun cualquier reivindicacion precedente, caracterizado porque el inhibidor de la MTP se selecciona del grupo constituido por: dirlotapida; mitratapida; (pentilcarbamoil-fenil-metil)-amida del ácido (S)-2-[(4'-trifluorometil-bifenil-2-carbonil)-amino]-quinolin-6-carboxílico; {[(4-fluoro-bencil)-metil-carbamoil]-fenil-metil}-amida del ácido (S)-2-[(4'-ter-butil-bifenil- 2-carbonil)-amino]-quinolin-6-carboxílico; [(4-fluoro-bencilcarbamoil)-fenil-metil]-amida del ácido (S)-2-((4'-ter-butil-bifenil-2-carbonil)-amino]-quinolin-6-carboxílico; {[(4-fluoro-bencil)-metil-carbamoill-fenil-metil}-amida del ácido (S)-2-((4'- isopropoxi-bifenil-2-carbonil)-amino]-quinolin-6-carboxilico; R256918 (1); o [2-(2H-[1,2,4]triazol-3-ilmetil)-1,2,3,4-tetrahidro-isoquinolein-6-il]-amida del ácido 4'-trifluorometil-bifenil-2-carboxílico; o una sal, solvato o hidrato de la misma farmacéuticamente aceptable.
ARP070105610A 2006-12-14 2007-12-13 Metodo para mejorar la apariencia corporal AR064343A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87001806P 2006-12-14 2006-12-14

Publications (1)

Publication Number Publication Date
AR064343A1 true AR064343A1 (es) 2009-04-01

Family

ID=39327425

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105610A AR064343A1 (es) 2006-12-14 2007-12-13 Metodo para mejorar la apariencia corporal

Country Status (4)

Country Link
JP (1) JP2008179612A (es)
AR (1) AR064343A1 (es)
TW (1) TW200833336A (es)
WO (1) WO2008072061A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558766A1 (en) 2004-03-05 2005-09-22 The Trustees Of The University Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
EP2404902A1 (en) * 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss

Also Published As

Publication number Publication date
WO2008072061A1 (en) 2008-06-19
JP2008179612A (ja) 2008-08-07
TW200833336A (en) 2008-08-16

Similar Documents

Publication Publication Date Title
US9790196B2 (en) Lysine demethylase inhibitors for diseases and disorders associated with Flaviviridae
WO2015183963A2 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
TW200614973A (en) Disposable wearing article
RU2015117267A (ru) Замещенные соединения амида
MY144232A (en) 5-substituted-2-phenylamino benzamides as mek inhibitors
CN111904962A (zh) 含有PDE4抑制剂和PI3 δ或双重PI3 δ-γ激酶抑制剂的药物组合物
GT200000057A (es) Compuestos para tratar la obesidad.
RU2005111229A (ru) Эндопротез локтевого сустава
UY29567A1 (es) "politerapia para tratar la obesidad o mantener la pcrdida de peso"
CY1109763T1 (el) Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης
WO2008051496A8 (en) Use of il-1 antagonists to treat gout and pseudogout
CN114835784A (zh) 抗炎肽及其用途
EA200900827A1 (ru) Фармацевтический состав, содержащий антагонист нейрокининов
EP3148565A2 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
Goldmeier et al. Persistent genital arousal in women–a new syndrome entity
AR064343A1 (es) Metodo para mejorar la apariencia corporal
EP0486809A2 (en) Use of suramin against TNF-related diseases
WO2015183988A1 (en) Therapeutic compositions including therapeutic small molecules and uses thereof
US11690848B2 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
US20190367503A1 (en) Compounds and methods of treating or ameliorating an il-1r-mediated disease or disorder using same
EA200800071A1 (ru) Производные бензофуранила как ингибиторы 5-нт6-рецептора
Auriemma et al. Cutaneous signs of classical dermatomyositis
JP2019523764A5 (es)
Keisuke et al. Action mechanisms of complementary and alternative medicine therapies for rheumatoid arthritis
JP6471366B2 (ja) インクレチンホルモン又はそのアナログを用いた変形性関節症の処置

Legal Events

Date Code Title Description
FB Suspension of granting procedure